News coverage about Syros Pharmaceuticals (NASDAQ:SYRS) has been trending somewhat positive recently, according to Accern Sentiment Analysis. The research group identifies positive and negative news coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Syros Pharmaceuticals earned a news impact score of 0.01 on Accern’s scale. Accern also assigned media coverage about the company an impact score of 46.7136703742724 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Here are some of the headlines that may have effected Accern Sentiment’s rankings:
- FY2021 EPS Estimates for Syros Pharmaceuticals, Inc. Cut by Oppenheimer Holdings (SYRS) (americanbankingnews.com)
- Syros Pharmaceuticals, Inc. (SYRS) Releases Earnings Results, Meets Expectations (americanbankingnews.com)
- Syros Reports Third Quarter 2017 Financial Results and Highlights Accomplishments and Upcoming Milestones (finance.yahoo.com)
- Syros Pharmaceuticals, Inc. (SYRS) Scheduled to Post Quarterly Earnings on Monday (americanbankingnews.com)
- Critical Review: Cardiome Pharma Corporation (CRME) vs. Syros Pharmaceuticals (SYRS) (americanbankingnews.com)
Syros Pharmaceuticals (NASDAQ:SYRS) traded down $0.28 during midday trading on Friday, hitting $11.34. 88,900 shares of the stock were exchanged, compared to its average volume of 160,922. Syros Pharmaceuticals has a one year low of $10.22 and a one year high of $24.38.
Syros Pharmaceuticals (NASDAQ:SYRS) last posted its earnings results on Wednesday, November 8th. The company reported ($0.53) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.53). research analysts forecast that Syros Pharmaceuticals will post -2.09 earnings per share for the current year.
A number of analysts have commented on the stock. Piper Jaffray Companies reiterated an “overweight” rating and issued a $30.00 price target on shares of Syros Pharmaceuticals in a research note on Tuesday, October 31st. Roth Capital assumed coverage on shares of Syros Pharmaceuticals in a research note on Monday, October 23rd. They issued a “neutral” rating and a $15.00 price target for the company. Zacks Investment Research upgraded shares of Syros Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, October 17th. JMP Securities upgraded shares of Syros Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $33.00 price target for the company in a research note on Thursday, September 28th. Finally, ValuEngine cut shares of Syros Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, September 22nd. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $26.14.
COPYRIGHT VIOLATION WARNING: “Syros Pharmaceuticals (SYRS) Receives Daily News Impact Rating of 0.01” was originally published by Markets Daily and is the sole property of of Markets Daily. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright law. The original version of this news story can be read at https://www.themarketsdaily.com/2017/11/12/syros-pharmaceuticals-syrs-receives-daily-news-impact-rating-of-0-01.html.
In other news, Director Richard A. Young sold 3,282 shares of the firm’s stock in a transaction dated Monday, August 14th. The shares were sold at an average price of $22.00, for a total transaction of $72,204.00. Following the completion of the sale, the director now owns 420,101 shares in the company, valued at approximately $9,242,222. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 33.60% of the company’s stock.
Syros Pharmaceuticals Company Profile
Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines.
Receive News & Ratings for Syros Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.